Treatment with tolebrutinib delayed the time to onset of 6-month CDP by 31% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib ...
Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...
SAN DIEGO — Tolebrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor that targets neuroinflammation, slowed disability progression by 31% in patients with nonrelapsing secondary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results